Retrospective Study on Data Aiming to Establish a Prediction Score for Return Home at the Time of Admission to a Multidisciplinary Medical Department (SCORDOM (SCORDOM)

February 23, 2024 updated by: Elsan

Retrospective Study on Data Aiming to Establish a Prediction Score for Return Home at the Time of Admission to a Multidisciplinary Medical Department

The goal of this observational study is to define clinical, biological and socio-cultural criteria, from the very first days of hospitalization on the multidisciplinary medicine department, to guide the patient's discharge from hospital (return to home when discharged from hospital).

The data collected will be those contained in the medical records of patients over 60 years of age who were admitted to the multidisciplinary medical department between October 2021 and February 2022 and between October 2022 and February 2023.

This study also aims at developing and validating a predictive score of orientation at the end of hospitalisation.

Participants are patients previously hospitalized. They will be informed about the study by post and will be able to object to the use of his or her data.

Study Overview

Status

Completed

Study Type

Observational

Enrollment (Actual)

600

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

      • Nancy, France, 54000
        • Hôpital Privé Nancy Lorraine

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

  • Adult
  • Older Adult

Accepts Healthy Volunteers

No

Sampling Method

Non-Probability Sample

Study Population

Patients over 60 years of age, hospitalized in Nancy private Hospital Lorraine, in the multidisciplinary medical department, between october 2021 and February 2022, and patients hospitalized between October 2022 and February 2023 (in the same department).

Description

Inclusion Criteria:

For the development of the score:

  1. All patients over 60 years of age admitted to the multidisciplinary medical department in the investigating center between October 2021 and February 2022.
  2. Patients for whom data of interest to this study are available in medical records.

For score validation :

  1. All patients aged over 60 admitted to the multidisciplinary medicine department of the investigating center between October 2022 and February 2023.
  2. Patients for whom data of interest to this study are available in medical records.

Exclusion Criteria:

  1. Patients transferred from an intensive care or continuing care unit
  2. Patients in palliative care
  3. Patients residing in an EHPAD (establishment for the elderly) or nursing home prior to hospitalization
  4. Patients without a minimum blood test on admission (blood test less than 48 hours old)
  5. Patients whose reason for hospitalization is due to COVID
  6. Patients who have objected to the use of their personal data

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

Cohorts and Interventions

Group / Cohort
Score development cohort
Patients over 60 years of age admitted to a general medicine department in the investigating center between October 2021 and February 2022
Score validation cohort
Patients over 60 years of age admitted to a general medicine department in the investigating center between October 2022 and February 2023

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Number of patients with a return to home after hospitalization and with similar clinical parameters, similar age category, similar pathology and similar biological parameters
Time Frame: Hospital stay, up to 3 weeks
Data collected among hospital data from october 2021 to february 2022. Clinical parameters measured: age, confusional syndrome, fever, eschar, blood pressure, etc; biological paremeters: (blood test performed in the last 2 days before discharge: albuminemia, natremia, protein C, Creatinemy, hemoglobinemy)
Hospital stay, up to 3 weeks

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Number of patients with a return to home after hospitalization and with similar clinical parameters, similar age category, similar pathology and similar biological parameters
Time Frame: Hospital stay, up to 3 weeks
Data collected among hospital data from october 2022 to february 2023. Clinical parameters measured: age, confusional syndrome, fever, eschar, blood pressure, etc; biological paremeters: (blood test performed in the last 2 days before discharge: albuminemia, natremia, protein C, Creatinemy, hemoglobinemy)
Hospital stay, up to 3 weeks

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Investigators

  • Principal Investigator: Anais Bauer, PhD, Hôpital Privé Nancy Lorraine

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

October 1, 2021

Primary Completion (Actual)

February 28, 2023

Study Completion (Actual)

February 28, 2023

Study Registration Dates

First Submitted

February 9, 2024

First Submitted That Met QC Criteria

February 23, 2024

First Posted (Estimated)

March 1, 2024

Study Record Updates

Last Update Posted (Estimated)

March 1, 2024

Last Update Submitted That Met QC Criteria

February 23, 2024

Last Verified

February 1, 2024

More Information

Terms related to this study

Other Study ID Numbers

  • Etude SCORDOM

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Continuity of Patient Care

3
Subscribe